Serina Therapeutics Operating Expenses Growth & History (SER)
Serina Therapeutics's operating expenses was $24.2M for fiscal 2025.
View full Serina Therapeutics company overviewSerina Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.2M | $7.0M | +41.21% |
| 2024 | 2024-12-31 | $17.1M | $10.8M | +172.27% |
| 2023 | 2023-12-31 | $6.3M | −$714,000 | −10.21% |
| 2022 | 2022-12-31 | $7.0M | −$1.2M | −14.31% |
| 2021 | 2021-12-31 | $8.2M | −$2.3M | −21.76% |
| 2020 | 2020-12-31 | $10.4M | −$3.6M | −25.69% |
| 2019 | 2019-12-31 | $14.0M | $1.8M | +14.38% |
| 2018 | 2018-12-31 | $12.3M | $2.6M | +27.18% |
| 2017 | 2017-12-31 | $9.7M | — | — |
Serina Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.8M | $1.1M | +19.12% |
| Q1 2026 | 2026-03-31 | $6.3M | $422,000 | +7.20% |
| Q4 2025 | 2025-12-31 | $6.2M | $672,000 | +12.14% |
| Q3 2025 | 2025-09-30 | $6.4M | $1.1M | +20.02% |
| Q2 2025 | 2025-06-30 | $5.7M | $1.8M | +45.39% |
| Q1 2025 | 2025-03-31 | $5.9M | $3.5M | +151.85% |
| Q4 2024 | 2024-12-31 | $5.5M | $2.7M | +94.48% |
| Q3 2024 | 2024-09-30 | $5.3M | $3.8M | +256.97% |
| Q2 2024 | 2024-06-30 | $3.9M | $3.0M | +311.45% |
| Q1 2024 | 2024-03-31 | $2.3M | $1.3M | +134.48% |
| Q4 2023 | 2023-12-31 | $2.8M | $1.1M | +59.08% |
| Q3 2023 | 2023-09-30 | $1.5M | −$62,000 | −3.99% |
| Q2 2023 | 2023-06-30 | $952,000 | −$645,000 | −40.39% |
| Q1 2023 | 2023-03-31 | $992,000 | −$1.1M | −51.75% |
| Q4 2022 | 2022-12-31 | $1.8M | −$104,000 | −5.49% |
| Q3 2022 | 2022-09-30 | $1.6M | −$142,000 | −8.37% |
| Q2 2022 | 2022-06-30 | $1.6M | −$632,000 | −28.35% |
| Q1 2022 | 2022-03-31 | $2.1M | −$290,000 | −12.36% |
| Q4 2021 | 2021-12-31 | $1.9M | −$587,000 | −23.67% |
| Q3 2021 | 2021-09-30 | $1.7M | −$753,000 | −30.75% |
| Q2 2021 | 2021-06-30 | $2.2M | −$181,000 | −7.51% |
| Q1 2021 | 2021-03-31 | $2.3M | −$750,000 | −24.22% |
| Q4 2020 | 2020-12-31 | $2.5M | −$706,000 | −22.16% |
| Q3 2020 | 2020-09-30 | $2.4M | −$1.2M | −32.74% |
| Q2 2020 | 2020-06-30 | $2.4M | −$1.4M | −36.06% |
| Q1 2020 | 2020-03-31 | $3.1M | −$351,000 | −10.18% |
| Q4 2019 | 2019-12-31 | $3.2M | −$305,000 | −8.74% |
| Q3 2019 | 2019-09-30 | $3.6M | $1.1M | +40.80% |
| Q2 2019 | 2019-06-30 | $3.8M | $1.3M | +49.62% |
| Q1 2019 | 2019-03-31 | $3.4M | −$234,000 | −6.36% |
| Q4 2018 | 2018-12-31 | $3.5M | — | — |
| Q3 2018 | 2018-09-30 | $2.6M | — | — |
| Q2 2018 | 2018-06-30 | $2.5M | — | — |
| Q1 2018 | 2018-03-31 | $3.7M | — | — |
Serina Therapeutics operating expenses trends
Over the last five fiscal years, Serina Therapeutics's operating expenses increased from $10.4M to $24.2M, a change of $13.7M. The latest reported quarter, Q2 2026, shows $6.8M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Serina Therapeutics source filings ↗